SG11202113333SA - Compounds and methods of use - Google Patents

Compounds and methods of use

Info

Publication number
SG11202113333SA
SG11202113333SA SG11202113333SA SG11202113333SA SG11202113333SA SG 11202113333S A SG11202113333S A SG 11202113333SA SG 11202113333S A SG11202113333S A SG 11202113333SA SG 11202113333S A SG11202113333S A SG 11202113333SA SG 11202113333S A SG11202113333S A SG 11202113333SA
Authority
SG
Singapore
Prior art keywords
compounds
methods
Prior art date
Application number
SG11202113333SA
Inventor
Christophe Frederic Portal
Original Assignee
Edinburgh Molecular Imaging Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1908573.7A external-priority patent/GB201908573D0/en
Priority claimed from GBGB2004360.0A external-priority patent/GB202004360D0/en
Application filed by Edinburgh Molecular Imaging Ltd filed Critical Edinburgh Molecular Imaging Ltd
Publication of SG11202113333SA publication Critical patent/SG11202113333SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4753Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202113333SA 2019-06-14 2020-06-15 Compounds and methods of use SG11202113333SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1908573.7A GB201908573D0 (en) 2019-06-14 2019-06-14 Compounds and methods of use
GBGB2004360.0A GB202004360D0 (en) 2020-03-26 2020-03-26 Compounds and methods of use
PCT/GB2020/051442 WO2020249980A1 (en) 2019-06-14 2020-06-15 Compounds and methods of use

Publications (1)

Publication Number Publication Date
SG11202113333SA true SG11202113333SA (en) 2021-12-30

Family

ID=71120198

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113333SA SG11202113333SA (en) 2019-06-14 2020-06-15 Compounds and methods of use

Country Status (12)

Country Link
US (1) US20220273830A1 (en)
EP (1) EP3983019A1 (en)
JP (1) JP2022537946A (en)
KR (1) KR20220034777A (en)
CN (1) CN114222592A (en)
AU (1) AU2020291197A1 (en)
BR (1) BR112021025124A2 (en)
CA (1) CA3142866A1 (en)
GB (2) GB2598676A (en)
MX (1) MX2021015467A (en)
SG (1) SG11202113333SA (en)
WO (1) WO2020249980A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023148680A1 (en) * 2022-02-04 2023-08-10 Advanced Accelerator Applications Methods for large scale synthesis of radionuclide complexes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2949658T1 (en) 2003-03-03 2018-10-30 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
NO20034350D0 (en) 2003-09-29 2003-09-29 Amersham Health As Optical imaging of colorectal cancer
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
US20130195756A1 (en) * 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
GB201223029D0 (en) * 2012-12-20 2013-02-06 Ge Healthcare Ltd Chelating agents
CN109824765B (en) * 2018-10-16 2020-11-17 哈尔滨医科大学 68Ga-labeled AEEA modified c-Met molecular imaging probe, preparation and application thereof

Also Published As

Publication number Publication date
GB202115731D0 (en) 2021-12-15
GB2589398A (en) 2021-06-02
CN114222592A (en) 2022-03-22
BR112021025124A2 (en) 2022-01-25
KR20220034777A (en) 2022-03-18
GB2598676A (en) 2022-03-09
JP2022537946A (en) 2022-08-31
GB202009064D0 (en) 2020-07-29
AU2020291197A1 (en) 2022-01-27
CA3142866A1 (en) 2020-12-17
WO2020249980A1 (en) 2020-12-17
EP3983019A1 (en) 2022-04-20
US20220273830A1 (en) 2022-09-01
GB2589398B (en) 2023-02-15
MX2021015467A (en) 2022-01-24

Similar Documents

Publication Publication Date Title
ZA201905677B (en) Glycan-interacting compounds and methods of use
IL279475A (en) Ectonucleotidase inhibitors and methods of use thereof
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL287751A (en) Kcnt1 inhibitors and methods of use
IL292810A (en) Therapeutic compounds and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
IL276687A (en) Trialkyne linking agents and methods of use
IL287973A (en) Acss2 inhibitors and methods of use thereof
IL285117A (en) Methods of characterizing condensate-associated characteristics of compounds and uses thereof
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
IL286697A (en) Neuregulin-4 compounds and methods of use
IL283782A (en) Anellosomes and methods of use
IL287966A (en) Auto-injector and related methods of use
GB201903827D0 (en) New compounds and methods
GB201903832D0 (en) New compounds and methods
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
EP3765485A4 (en) Immuno-exosomes and methods of use thereof
EP3761989A4 (en) Imidazodiazepinediones and methods of use thereof
IL276053A (en) Therapeutic-gard and method of use thereof
GB2589398B (en) Compounds and methods of use
EP3793552C0 (en) Abhd12 inhibitors and methods of making and using same
ZA202105399B (en) Use of spiropidion
EP3976039A4 (en) Bisaminoquinolines and bisaminoacridines compounds and methods of their use
EP3836966A4 (en) Catabodies and methods of use thereof